Peptide transport by the multidrug resistance protein MRP1.
暂无分享,去创建一个
M. Kool | R. Meloen | W. Puijk | G. Scheffer | R. Scheper | J. Slootstra | H. Broxterman | M. C. de Jong | A. B. Schroeijers | W. Puijk | M. C. D. Jong | R. Dinkelberg | Marcel Kool | R. J. Scheper | Remco Dinkelberg | Rob H. Meloen
[1] E. Wiemer,et al. Lung resistance-related protein/major vault protein and vaults in multidrug-resistant cancer , 2000, Current opinion in oncology.
[2] M. Kool,et al. Specific detection of multidrug resistance proteins MRP1, MRP2, MRP3, MRP5, and MDR3 P-glycoprotein with a panel of monoclonal antibodies. , 2000, Cancer research.
[3] D. Hipfner,et al. Structural, mechanistic and clinical aspects of MRP1. , 1999, Biochimica et biophysica acta.
[4] Holland Ib,et al. ABC-ATPases, adaptable energy generators fuelling transmembrane movement of a variety of molecules in organisms from bacteria to humans. , 1999 .
[5] R. Miller,et al. mdr1a-encoded P-glycoprotein is not required for peripheral T cell proliferation, cytokine release, or cytotoxic effector function in mice. , 1999, Journal of immunology.
[6] L. Doyle,et al. Erratum: A multidrug resistance transporter from human MCF-7 breast cancer cells (Proceedings of the National Academy of Sciences of the USA (December 22, 1998) 95 (15665-15670)) , 1999 .
[7] R. Evers,et al. Canalicular multispecific organic anion transporter/multidrug resistance protein 2 mediates low-affinity transport of reduced glutathione. , 1999, The Biochemical journal.
[8] P. Jansen,et al. ATP‐ and glutathione‐dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1 , 1999, British journal of pharmacology.
[9] I. Holland,et al. ABC-ATPases, adaptable energy generators fuelling transmembrane movement of a variety of molecules in organisms from bacteria to humans. , 1999, Journal of molecular biology.
[10] I. Pastan,et al. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. , 1999, Annual review of pharmacology and toxicology.
[11] L. Doyle,et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[12] S. Cole,et al. Characterization of vincristine transport by the M(r) 190,000 multidrug resistance protein (MRP): evidence for cotransport with reduced glutathione. , 1998, Cancer research.
[13] F. Sharom,et al. Linear and cyclic peptides as substrates and modulators of P-glycoprotein: peptide binding and effects on drug transport and accumulation. , 1998, The Biochemical journal.
[14] B. Tran,et al. Probenecid reverses multidrug resistance in multidrug resistance-associated protein-overexpressing HL60/AR and H69/AR cells but not in P-glycoprotein-overexpressing HL60/Tax and P388/ADR cells , 1997, Cancer Chemotherapy and Pharmacology.
[15] F. Sharom,et al. Synthetic hydrophobic peptides are substrates for P-glycoprotein and stimulate drug transport. , 1996, The Biochemical journal.
[16] S. Zhao,et al. Involvement of P-glycoprotein in the transmembrane transport of interleukin-2 (IL-2), IL-4, and interferon-gamma in normal human T lymphocytes. , 1996, Blood.
[17] F. Baas,et al. Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[18] D. Meijer,et al. Hepatobiliary secretion of organic compounds; molecular mechanisms of membrane transport. , 1995, Biochimica et biophysica acta.
[19] N. Feller,et al. ATP‐dependent efflux of calcein by the multidrug resistance protein (MRP): no inhibition by intracellular glutathione depletion , 1995, FEBS letters.
[20] S. Howell,et al. Cross-resistance between cisplatin and antimony in a human ovarian carcinoma cell line. , 1994, Cancer Research.
[21] G. M. Wilson,et al. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. , 1994, Cancer research.
[22] C. Meijer,et al. Immunochemical detection of the multidrug resistance-associated protein MRP in human multidrug-resistant tumor cells by monoclonal antibodies. , 1994, Cancer research.
[23] M. Gottesman,et al. Interaction of bioactive hydrophobic peptides with the human multidrug transporter , 1994, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[24] J. Neefjes,et al. Selective and ATP-dependent translocation of peptides by the MHC-encoded transporter. , 1993, Science.
[25] M. Barrand,et al. Chemosensitisation and drug accumulation effects of cyclosporin A, PSC-833 and verapamil in human MDR large cell lung cancer cells expressing a 190k membrane protein distinct from P-glycoprotein. , 1993, European journal of cancer.
[26] T. Ishikawa,et al. The ATP-dependent glutathione S-conjugate export pump. , 1992, Trends in biochemical sciences.
[27] R. Schimke,et al. Peptide transport by the multidrug resistance pump. , 1992, The Journal of biological chemistry.
[28] P. Twentyman. Cyclosporins as drug resistance modifiers. , 1992, Biochemical pharmacology.
[29] N. Roehm,et al. An improved colorimetric assay for cell proliferation and viability utilizing the tetrazolium salt XTT. , 1991, Journal of immunological methods.
[30] A. Meister. Glutathione deficiency produced by inhibition of its synthesis, and its reversal; applications in research and therapy. , 1991, Pharmacology & therapeutics.
[31] D. Scudiero,et al. New colorimetric cytotoxicity assay for anticancer-drug screening. , 1990, Journal of the National Cancer Institute.
[32] J. Bulte,et al. Monoclonal antibody JSB‐1 detects a highly conserved epitope on the P‐glycoprotein associated with multi‐drug‐resistance , 1988, International journal of cancer.
[33] M. Center,et al. Adriamycin resistance in HL60 cells in the absence of detectable P-glycoprotein. , 1987, Biochemical and biophysical research communications.
[34] R. Ozols,et al. Reversal of adriamycin resistance by verapamil in human ovarian cancer. , 1984, Science.